Company intelligence / Profile preview
Cassava Sciences
Austin, Texas, United Statescassavasciences.com ↗
- Ownership
- Public · SAVA
- Employees
- ~25
- Development stage
- Other
01
Overview
Simufilam, the company’s lead oral small molecule targeting filamin A for Alzheimer’s disease, failed to show clinical benefit in two large Phase 3 trials (RETHINK-ALZ and REFOCUS-ALZ). Both studies did not meet their primary endpoints and were discontinued in late 2024. The company has since ended its Alzheimer’s program but is exploring simufilam for other central nervous system disorders such as TSC-related epilepsy[2][4][6].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
No major pharma or biotech partnerships disclosed publicly as of May 2025.
Beyond the preview
Go deeper on Cassava Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cassava Sciences.